Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Kaerus Bioscience Logo
Kaerus Bioscience CB Rank
646016
Heat Score
35
Kaerus Bioscience develops clinical-stage therapeutics for Fragile X syndrome and related neurodevelopmental disorders.
Founded
obfuscation
Private London, England, United Kingdom11-50 kaerusbio.com
Biotechnology
Clinical Trials
Therapeutics
Overview

Kaerus Bioscience
Heat Score
35

Growth Score
pts
in past quarter
Heat Score 35
-24 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Kaerus Bioscience

CB Rank
646016
Kaerus Bioscience develops clinical-stage therapeutics for Fragile X syndrome and related neurodevelopmental disorders.
Founded
obfuscation
Private London, England, United Kingdom11-50 kaerusbio.com
Biotechnology
Clinical Trials
Therapeutics

Key People

Details

Legal Name Kaerus Bioscience Ltd.
Operating Status Active
Company Type For Profit
Founders  Olivier Perche, Sylvain Briault
Contact Email info@kaerusbio.com
Predictions & Insights

Growth Insight

See this Growth Insight
Kaerus Bioscience is
Lorem
 to be growing
Top Contributing Factors
Operations Contraction

Growth Prediction

See this Growth Prediction

Products & Services

KER-0193
An orally-bioavailable small molecule modulator of BK channels designed to address brain hyper-excitability in Fragile X syndrome.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 2 Contacts 1

Employee Profiles

News

News and Press

News•Jan 27, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jan 27, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Sep 9, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Sep 8, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Active Website Tech Count

4Kaerus Bioscience is actively using 4 technologies for its website, according to BuiltWith. These include Common Crawl, Euro, and  CommonCrawl Top 5m.

Total IP

1Kaerus Bioscience has 1 registered patent in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Kaerus Bioscience's headquarters? Kaerus Bioscience is located in London, England, United Kingdom.Who are Kaerus Bioscience's competitors? Alternatives and possible competitors to Kaerus Bioscience may include Roche, QurAlis, and  Spinogenix.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5eb04bf 1)
|